Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder

  title={Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder},
  author={Renee-Marie Ragguett and Carola Rong and Joshua D. Rosenblat and Roger Chun-Man Ho and Roger S. McIntyre},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={475 - 482}
ABSTRACT Introduction: Treatment resistant depression (TRD) represents approximately 20% of all individuals receiving care for major depressive disorder. The opioidergic system is identified as a novel target which hitherto has not been sufficiently investigated in adults with TRD. The combination product buprenorphine + samidorphan is an opioid modulatory agent which has demonstrated replicated evidence of efficacy in TRD without abuse liability. Areas covered: Databases Pubmed, Google Scholar… Expand
8 Citations
Keeping up with the clinical advances: depression
Rapid response pharmaceuticals have the potential to transform the treatment of MDD, demonstrating reduction in depressive symptoms within 24 hours, as opposed to weeks noted with conventional antidepressants. Expand
Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder.
Depression history continues to be associated with good opioid outcomes in adjusted models, and more research is needed to understand how these factors could improve treatment outcomes for those with opioid use disorder. Expand
Modulation of the central opioid system as an antidepressant target in rodent models.
This approach acknowledges that targeting a single opioid receptor may not be sufficient to produce the balanced profile of therapeutic effects, while minimizing adverse effects, and begins to examine combining of opioid agents, conferring unique profiles. Expand
Dynorphin and the Kappa Opioid Receptor’s Role in the Symptomatology of Schizophrenia: A Review of the Evidence
An overview of the kappa system is presented and various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the positive and negative symptoms of schizophrenia are reviewed. Expand
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
Relative bioavailability of OLZ in ALKS 3831, a bilayer tablets containing OLZ and SAM, a matching bilayer tablet containingOLZ only (OLZ), and Zyprexa (brand olanzapine [B‐OLZ]) was assessed in an open‐label study, demonstrating bioequivalence of OLz in AL KS 3831. Expand
A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior
CERC‐501 was well tolerated, but it did not significantly alter the latency to start smoking or the number of cigarettes smoked, and did not affect cigarette craving, mood, anxiety, nicotine withdrawal, or subjective effects of smoking. Expand
Mice Lacking GABAA Receptor δ Subunit Have Altered Pharmaco-EEG Responses to Multiple Drugs
Findings on pharmaco-EEG effects of 4-MMC suggest that δ-GABAARs are involved in the secondary indirect regulation of the brain rhythms after 4- MMC, and stimulants are not known to act on these receptors. Expand


Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
The buprenorphine/samidorphan combination is a novel and promising candidate for treatment of major depressive disorder in patients who have an inadequate response to standard antidepressants. Expand
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression, but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects. Expand
Evaluation of Opioid Modulation in Major Depressive Disorder
A combination of BUP and SAM showed antidepressant activity in subjects with MDD, and Balanced agonist–antagonist opioid modulation represents a novel and potentially clinically important approach to the treatment of MDD and other psychiatric disorders. Expand
The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
Ketamine has been demonstrated to be rapidly effective and was associated with a significant clinical improvement in depressive symptoms within hours after administration, confirming the active role of glutamate in the pathophysiology of this complex condition. Expand
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Investigation of buprenorphine pharmacokinetics by different routes of administration at dosages approximating those used in opioid-dependence studies found that the terminal elimination half-life of norbuprenorphines was longer than bupenorphine and the mean peak plasma concentrations were less than 1 ng/mL. Expand
Psychotherapeutic Benefits of Opioid Agonist Therapy
  • P. Tenore
  • Psychology, Medicine
  • Journal of addictive diseases
  • 2008
This article reviews the medical literature on the treatment of psychiatric disorders with opioids (notably, methadone and buprenorphine) in both the non-opioid-dependent population and in the opioid-dependent Methadone maintenance population. Expand
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
The pharmacokinetic and pharmacodynamic properties of buprenorphine allow it to be a feasible option for substitution therapy in the treatment of opioid dependence. Expand
Venlafaxine and mirtazapine
It is speculated that the involvement of the opioid system in the antidepressants’ mechanism of action may be necessary, in order to prove effective in the treatment of severe depression, unlike the SSRIs and other antidepressants which lack opioid activity. Expand
Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
In these single- and multiple-dose studies in healthy volunteers, samidorphan exhibited a pharmacokinetic profile consistent with once-daily dosing, with somnolence reported as the most common adverse event. Expand
Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression?
It is speculated that the involvement of the opioid system in the antidepressants' mechanism of action may be necessary, in order to prove effective in the treatment of severe depression, unlike the SSRIs and other antidepressants which lack opioid activity. Expand